Cyclacel Pharmaceuticals Inc [CYCC] stock prices are up 9.76% to $0.45 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The CYCC shares have gain 8.41% over the last week, with a monthly amount drifted -44.68%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
On September 07, 2018, Ladenburg Thalmann initiated with a Buy rating. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $5 on October 16, 2015. Roth Capital initiated its recommendation with a Buy and recommended $7 as its price target on February 04, 2010. In a note dated August 12, 2008, Piper Jaffray initiated an Buy rating and provided a target price of $5 on this stock.
The stock price of Cyclacel Pharmaceuticals Inc [CYCC] has been fluctuating between $0.38 and $8.65 over the past year. Currently, Wall Street analysts expect the stock to reach $1 within the next 12 months. Cyclacel Pharmaceuticals Inc [NASDAQ: CYCC] shares were valued at $0.45 at the most recent close of the market. An investor can expect a potential return of 122.22% based on the average CYCC price forecast.
Analyzing the CYCC fundamentals
The Cyclacel Pharmaceuticals Inc [NASDAQ:CYCC] reported sales of 0.08M for trailing twelve months, representing a drop of -98.93%. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -260.68%, Pretax Profit Margin comes in at -265.41%, and Net Profit Margin reading is -179.28%. To continue investigating profitability, this company’s Return on Assets is posted at -2132.68, Equity is 76.38 and Total Capital is 17202.24.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.3737 points at the first support level, and at 0.2974 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.5238, and for the 2nd resistance point, it is at 0.5976.
Ratios To Look Out For
It’s worth pointing out that Cyclacel Pharmaceuticals Inc [NASDAQ:CYCC]’s Current Ratio is 1.07. On the other hand, the Quick Ratio is 1.07, and the Cash Ratio is 0.47. Considering the valuation of this stock, the price to sales ratio is 12.07, the price to book ratio is 0.81.
Transactions by insiders
Recent insider trading involved McBarron Paul, that happened on Dec 21 ’23 when 1886.0 shares were purchased. President and CEO, Rombotis Spiro George completed a deal on Dec 21 ’23 to buy 6070.0 shares.
